Do overuse of antibiotics and animal health matter to investors?
The problem of Antimicrobial Resistance (AMR) is at a critical point. Yet, when talking about the animal agriculture sector, investors tend to focus on emission reduction, deforestation, and recently also alternative proteins. AMR is a systemic global risk to public health and the economy. The estimated cost in terms of lost global production could reach USD $100 trillion by 2050 if we do not take action. So what do investors need to know about it?
On the 19th of January, our Senior Manager, Research and Engagements, Jo Raven, will join Dana Hanby, Managing Director, ESG Nexus, to discuss the excessive and unnecessary use of antibiotics in agriculture.
|Date:||19th January 2022|
|Time:||15:00 - 16:00|